resent a shift in age predominance such as has been referred to previously for Central Europe. 5 Despite the reduction in worldwide incidence of PSGN, epidemics and clusters of cases of PSGN continue to appear. Table 1 lists epidemics with Ͼ100 cases 10, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and Table 2 the epidemics with Ͻ100 cases or clusters in families or communities. 9, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Figure  1 shows that in the past 30 yr, large epidemics have been reported in countries in the middle range of the Human Development Index (HDI; between the 48th and the 87th rank place out of 177) and clusters of cases in countries in the upper 10% of the HDI. 43 The countries where PSGN has not been reported in the past 30 yr are in the socalled "low" range of the HDI (0.449 to 0.336), 43 and overwhelming social and health problems in combination with poor documentation resources ( Figure  1A ) are likely reasons for the apparent absence of PSGN.
In the past 30 yr, most of the smaller epidemics and clusters of cases are reported from poor communities, rural and/or Aboriginal, within countries in the upper 10% range of the HDI (Figure 1B) . In these countries, the annual per capita health expenditure is nearly 5 times higher than that in countries where large epidemics are reported ( Figure 1A ) and is likely that the more efficient and better funded public health system in these nations facilitates the recognition and early antibiotic treatment of streptococcal infections in index cases of PSGN. Similarly, underprivileged communities in less developed nations may also have clusters of cases of acute PSGN that go unreported. The data reviewed here suggest that PSGN remains a significant health problem in underdeveloped countries. Additional insight into the potential burden of PSGN in these nations may be gained from the evaluation of the incidence of the most severe cases of the disease in pediatric referral hospitals. Acute postinfectious glomerulonephritis is frequently the cause of severe acute renal failure (requiring dialysis and/or admission to pediatric intensive care units) in underdeveloped countries. The proportion of cases of acute renal failure that correspond to acute postinfectious glomerulonephritis of demonstrated or assumed poststreptococcal etiology is 13% in New Delhi, 44 30% in Istanbul, 45 51 .6% in Casablanca, 46 4 .6% in Lagos, 47 27% in Bombay, 48 19 .2% in Lucknow, 49 33% in Asunció n, 50 17 .4% in Chandrigarth, 51 5 .2% in Lima, 52 9 .3% in Varanasi, 53 and 25% in Osun State, Nigeria. 54 
GLOBAL BURDEN OF ACUTE PSGN
Carapetis et al., 55 using 11 population studies reporting the incidence of acute PSGN, evaluated the global burden of PSGN. In children from less developed countries and minority populations, they found that the median incidence of disease was 24.3 cases per 100,000 person-years. In people older than 15 yr in these same countries, they estimated the incidence to be two cases per 100,000 person-years, basing their calculations on data from Kuwait. In more developed countries, the incidence was estimated at 0.3 cases per 100,000 person-years on the basis of the Italian Biopsy Registry. The global incidence of acute PSGN was estimated at 472,000 cases per year, 456,000 of which occurred in less developed countries.
Estimations of the global burden of PSGN may also be approached by considering that cases of PSGN with severe acute renal failure, usually as a result of a rapidly progressive course and crescentic glomerulonephritis, represent Ͻ1% of the total number of cases. 56 These cases derive from reports of pediatric acute renal failure from underdeveloped countries. In this study, the following assumptions were made: The patients with acute glomerulonephritis represented cases of PSGN. This was explicitly stated in most series but not in all of them; the cases listed had severe renal failure because they were seen at a referral hospital and admitted to intensive care units if the facility was available, and most underwent dialysis; and the total number of cases of acute PSGN in the general population was estimated assuming that uncomplicated cases were 100 (low estimate) to 300 (high estimate) more than lifethreatening disease. The calculations are shown in Tables 3 and 4 . Figure 1 . Large epidemics (Ͼ100 cases) and clusters of cases of PSGN reported in the past 30 yr. (A) Reports are related to the HDI rank of the country in which the outbreak occurred. 43 Annual public health expenditure data obtained from the World Health Organization. 108 (B) The mean HDI in the countries were large epidemics are reported is significantly lower than the HDI in the countries with smaller epidemics and clusters break have been reported. ***P Ͻ 0.001.
SPECIAL ARTICLE www.jasn.org bles 1 and 2), and, therefore, nephritogenic antigens are present and possibly shared by streptococci from several groups. 3 Two antigens are actively investigated at the present time as the potential cause(s) of PSGN: The nephritis-associated plasmin receptor (NAPlr), identified as glyceraldehyde-3-phosphate dehydrogenase, 59 ,60 and a cationic cysteine proteinase known as streptococcal pyrogenic exotoxin B (SPEB) that is generated by proteolysis of a zymogen precursor (zSPEB). [61] [62] [63] Both of these fractions are capable of activating the alternate pathway of the complement system. 3 NAPlr deposits are present in early biopsies of acute PSGN, and NAPlr antibody levels are detected by Western blot in convalescent sera of 92% of the patients with PSGN and 60% of uncomplicated streptococcal infections in Japan. 59 Because NAPlr is co-localized with plasmin but not with complement or IgG, nephritogenicity is related to plasminbinding capacity, which facilitates immune complex deposition and subsequent inflammation. 60 More recent investigations by Fujino et al. 64 demonstrated that the gene sequence and in vitro expression of NAPlr is not restricted to strains isolated from patients with PSGN and is also present in streptococci from groups A, C, and G. SPEB/zSPEB is produced by nephritogenic streptococci from group A. 65 Four independent studies (Oda and Yoshizawa, National Defense Medical College, Saitama, Japan, personal communication, December 27, 2007, see last paragraph of this section) 62, 63, 66 showed that SPEB/zSPEB is deposited in biopsies of patients with acute PSGN and that high antibody titers to this antigen are present in convalescent sera of the vast majority of patients sampled in Latin America. 62 Subsequent studies 66 evaluated both NAPlr and SPEB in serum and biopsies obtained from patients in Venezuela, Chile, and Switzerland and detected SPEB deposits in 12 of 17 biopsies and serum anti-SPEB antibodies in 53 of 53 sera. In contrast, in the same material, circulating antibodies to NAPlr were found in only five of 47 sera and definite glomerular deposits in only one biopsy. SPEB co-localizes with complement deposits and within subepithelial electrondense deposits (humps) that are the typical signature of acute PSGN. Thus far, this represents the only demonstration of a putative nephritogenic antigen inside the humps and suggests this localization was facilitated by the cationic, antigenic charge of SPEB, as postulated in previous studies. 67, 68 The contrasting results in antibody response and renal deposits of NAPlr and SPEB in patients from Japan and patients elsewhere suggest there may be more than a single streptococcal antigen responsible for glomerulonephritis, and different antigenic fractions could be nephritogenic in populations of different genetic background. In support of this conclusion are studies (see last paragraph of this article) demonstrating the absence of the gene encoding SPEB in the S. zooepidemicus responsible for the recent epidemic of glomerulonephritis in Brazil. 23 Studying this same strepto- 70, 71 and NAPlr 72 are capable of inducing chemotactic (monocyte chemoattractant protein 1) and IL-6 moieties in mesangial cells, promoting enhanced expression of adhesion molecules. Recent investigations also demonstrated peripheral blood leukocytes respond with release of IL-6, TNF-␣, IL-8, and TGF-␤ when reacted with SPEB. 73 These findings underline the inflammatory potential of these putative nephritogens.
The role of plasmin-binding activity in the pathogenesis of PSGN is an attractive possibility. The plasmin-binding activity of both NAPlr 60 and SPEB 61 is widely recognized. Similar properties are present in streptokinase and enolase, and the nephritogenic potential of the latter is based on its plasmin-binding properties. 74 Recent investigations by Oda and co-workers (National Defense Medical College, Saitama, Japan, personal communication, December 27, 2007) demonstrated by doublestaining method that NAPlr and SPEB both are localized in the glomerular mesangium of biopsies of patients with acute PSGN (Figure 2 ) and because they found similar localization of both antigens postulated that plasmin-binding activity may be a common nephritogenic characteristic in both antigens.
TREATMENT GUIDELINES FOR STREPTOCOCCAL INFECTIONS WITH POTENTIAL FOR GLOMERULONEPHRITIS
Acute PSGN is prevented by early antibiotic treatment, and the spread of nephritisassociated streptococcal infection is contained by prophylactic antibiotic treatment to individuals at risk. The challenge is to define who should be treated when the diagnosis of streptococcal infection is uncertain and when prophylactic treatment of a given population is warranted. The decision is straightforward with active skin infections because the differential diagnosis is between staphylococcal and streptococcal impetigo, and both should be treated with penicillin except when methicillin-resistant staphylococci are prevalent in the community.
In contrast, the diagnosis of streptococcal pharyngitis on clinical grounds alone is uncertain, and only 10 to 20% of the patients who present with a sore throat in general clinical practice have a positive culture for group A Streptococcus. 75 Because clinical judgment may miss half of the streptococcal pharyngitis and wrongly identify as such 20 to 40% of the cases of sore throats, 76 several clinical scoring systems have been developed to increase the accuracy of diagnosis for the prescription of antibiotics. Among the most popular are the scores proposed by Centor et al. 77 and McIsaac et al. 78 that have a range from 0 to 4 and incorporate age as a risk factor. The McIsaac score gives 1 point each to the following criteria: Temperature Ͼ38°C, no cough, tender anterior cervical adenopathy, tonsillar swelling or exudates, and age between 3 and 14 yr. Age 15 to 44 yr is assigned no points, and age Ն44 yr gets Ϫ1 point. Using this scoring system, the sensitivity and specificity of the diagnosis are 85 and 92%, respectively 79 ; and in practical terms, antibiotic treatment is recommended on clinical grounds alone when the score is 4, antibiotic treatment is not recommended (and culture is unnecessary) when the score is 0 or 1, and cultures should be obtained and treatment given only when the result is positive when score is 2 or 3. Rapid tests for streptococcal antigen detection suitable for office practice have been developed and may be used as a confirmatory test for children with tonsillar exudate and no cough, 80 but their sensitivity is too low to support use without culture confirmation of negative results. 81 Patients with acute PSGN should be treated as though they have active streptococcal infection. The reason for this recommendation is that positive cultures may sometimes be obtained from patients in whom upper respiratory or skin infections are not clinically evident. Treatment of a carrier state may prevent spread to other household members; in addition, at least one report suggested that patients who receive PSGN antibiotic treatment have a milder clinical course. 82 Prophylactic penicillin treatment should be used in epidemics in closed communities and prescribed to household contacts of index cases in areas where PSGN is very common or when clusters of cases are reported. This recommendation is based on the finding that cross-infection among family members of index cases in communities where PSGN is prevalent is very high. In Maracaibo, 95% of the siblings and 79% of the parents of index cases presented serologic evidence of recent streptococcal infection. 83 Studies of Australian Aboriginal communities also supported this notion. Johnston et al. 30 found treatment with benzathine penicillin G targeted to children with skin sores and household contacts of index cases prevented new cases of acute PSGN, in contrast with the SPECIAL ARTICLE www.jasn.org incidence in communities in which no intervention was attempted.
PROGNOSIS OF PSGN
The immediate prognosis of acute PSGN is excellent for children. In contrast, elderly patients who develop acute PSGN usually present with debilitating conditions (malnutrition, alcoholism, diabetes, or chronic illness) and have a high incidence of azotemia (60%), congestive heart failure (40%), and proteinuria in the nephrotic range (20%). Death may occur in as many as 20 to 25% of these patients. 84, 85 The long-term prognosis of PSGN in children has been the subject of many studies. The initial reports of natural history of PSGN in the first half of the 20th century indicated an excellent prognosis, but follow-up periods were relatively short. Subsequent studies gave conflicting results because abnormal urinary findings were as low as 3.5% 86 and as high as 60%. 87 Table 5 summarizes the results of several studies published before the year 2000 with 5 to 18 yr of follow-up. 86 -93 These pooled data, of course, come from studies with dissimilar methods and widely different results and therefore is presented only as a rough approximation of what to expect in the long-term natural history of PSGN. Table 6 shows data from the three studies reported after 2000. 94 -96 When all studies reporting children followed for 10 to 20 yr after acute PSGN are taken into account, approximately 20% of the patients have abnormal urine analyses, but the incidence of azotemia is Ͻ1%. Our own data 94 include 110 children followed for 15 to 18 yr after the acute episode PSGN and show an incidence of 7.2% for non-nephrotic proteinuria, 5.4% for microhematuria, 3.0% for hypertension, and 0.9% for azotemia. A particularly bad prognosis was reported for patients from a recent epidemic in Minas Gerais (Brazil), a majority of which were adults (Table 6). Chronic renal failure developed in 8% of these patients after 5 yr. 95 Carefully collected data in Aboriginal communities in the Northern Territory of Australia indicated that PSGN is associated with an increased risk for albuminuria (adjusted OR 6.1%; 95% confidence interval 2.2 to 16.9) and hematuria (OR 3.7; 95% confidence interval 1.8 to 8.0) in relation to control subjects who did not have PSGN. 96 From the previous discussion, it follows that, in general, chronic renal failure resulting from PSGN is exceptional but specific groups of patients do not share this favorable outlook. A group of patients with especially poor long-term prognosis are elderly patients who develop persistent proteinuria in the nephrotic range; 77% of these patients develop chronic renal failure. 97 For children, the prognosis of PSGN may be significantly worse in specific communities in which other risk factors for chronic renal failure are common. This is the case in Australian Aboriginal communities, where low birth weight (resulting in the endowment of a low nephron number), diabetes, and metabolic syndrome are prevalent. White et al. 96 postulated that PSGN may represent an additional risk factor that would explain why the incidence of ESRD is severalfold higher in these communities than in the non-Aboriginal population. 98, 99 
PRESENT AND FUTURE ROLE OF STREPTOCOCCAL GENOMICS IN PSGN
In the past 8 yr, application of genomewide investigative strategies to unsolved problems with group A Streptococcus has contributed significant new information about molecular events occurring during host-pathogen interactions. 100 -102 These new techniques include, among others, bacterial genome sequencing, expression microarray (transcriptome) analysis, comparative genomics by DNA-DNA microarray analysis, and proteomics. 99 For example, we now have genome sequences available for 11 strains of group A Streptococcus recovered from diverse types of infection, making this organism one of the most extensively characterized of any human bacterial pathogen. 100 This remarkable array of new information gives new insight into the pathogenesis of pharyngitis, acute rheumatic fever, puerperal sepsis, and other invasive infections and has allowed identification of vaccine targets 99, 100 ; however, notably absent has been the application of these new techniques to problems in PSGN.
As a consequence, one of us (J.M.M.) recently began a molecular genomics initiative designed to contribute new information about the pathogenesis of PSGN, aimed at providing new leads for subsequent clinical and translational research. One of the first goals has been to sequence the genome of streptococcal strains causing or repeatedly associated with PSGN (so-called "nephritogenic" strains) and compare their genetic makeup with the genome of strains not associated with PSGN ("non-nephritogenic" strains). Using this approach, Beres et al. 102 found considerable genetic differences in nephritogenic and nonnephritogenic strains of serotype M12 Streptococcus. For example, the nephritogenic strain had a large segment of DNA, referred to as region of difference 2 (RD.2), that was lacking in the non-nephritogenic strain. RD.2 encodes a large, predicted, exported protein that is not made by other sequenced group A Streptococcus strains and thus warrants further investigation in the context of PSGN pathogenesis. More recently, as noted, we have sequenced the genome of a strain of S. zooepidemicus causing a large nephritis outbreak after the ingestion of unpasteurized milk from cows with mastitis. Unexpected, the gene encoding SPEB, one of the secreted bacterial products that contribute to the survival of Streptococcus in saliva, was absent. 103 Further analysis of the genomic sequence revealed that a large block of DNA encoding SPEB present in all group A Streptococcus strains studied to date is missing in this strain, perhaps as a result of a deletion event (unpublished data). This finding is important because SPEB has been implicated in the pathogenesis of PSGN (see the Nephritogenic Antigens section), and the genomic data clearly indicate that if it participates, then it cannot be the sole causative molecule in all patients. Molecular proteogenomics are also at the crossroads of a paradigm shift in vaccine research toward the strategy of "reverse vaccinology." 104 -106 This strategy consists of using a complete genomic sequence to identify large numbers of potentially protective antigens, expressing them in a recombinant form, and then testing them with a battery of immunologic assays. These powerful new tools perhaps coupled with renewed interest in nonhuman primate models of streptococcal infection 101,107 are likely to usher a new era of the study of PSGN. 
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